Low-molecular-weight heparins: Are they all the same?

British Journal of Haematology

Volumn 121, Issue 1, 2003, Pages 12-20

  White, Richard H ^a,b,c   Ginsberg, Jeffrey S ^d  

^a PSSB   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

Comparison; Daltaparin; Enoxaparin; Low molecular weight heparin; Tinzaparin

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

BLEEDING; CELL FRACTIONATION; CLINICAL TRIAL; DEPOLYMERIZATION; DRUG EFFICACY; DRUG SYNTHESIS; HEART INFARCTION; HUMAN; HYDROLYSIS; MEDLINE; PRIORITY JOURNAL; REVIEW; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANGINA, UNSTABLE; BLOOD COAGULATION TESTS; DALTEPARIN; ENOXAPARIN; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0037394009     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04196.x     Document Type: Review

References (51)

1. Alban, S. & Gastpar, R. (2001) Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thrombosis and Haemostasis, 85, 824-829.
2. Andrassy, K. & Eschenfelder, V. (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thrombosis Research, 81, s29-s38.
3. Antman, E.M., McCabe, C.H., Gurfinkel, E.P., Turpie, A.G., Bernink, P.J., Salein, D., Bayes De Luna, A., Fox, K., Lablanche, J.M., Radley, D., Premmereur, J. & Braunwald, E. (1999) Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation, 100, 1593-1601.
4. Bara, L., Planès, A. & Samama, M.M. (1999) Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low-molecular-weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. British Journal of Haematology, 104, 230-240.
5. Bendz, B., Andersen, T.O. & Sandset, P.M. (2000) Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagulation and Fibrinolysis, 11, 343-348.
6. Bick, R.L. & Fareed, J. (1999) Low molecular weight heparins: differences and similarities in approved preparations in the United States. Clinical Applied Thrombosis and Hemostasis, 5, s63-s66.
7. Carrie, D., Caranobe, C. & Boneu, B. (1993) A comparison of the antithrombotic effects of heparin and of low-molecular-weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit. British Journal of Haematology, 83, 622-626.
8. Cohen, M., Demers, C., Gurfinkel, E.P., Turpie, A.G., Fromell, G.J., Goodman, S., Langer, A., Califf, R.M., Fox, K.A., Premmereur, J. & Bigonzi, F. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. New England Journal of Medicine, 337, 447-452.
9. Davidoff, F. (2001) The heartbreak of drug pricing. Annals of International Medicine, 134, 1068-1071.
10. Dolovich, L.R., Ginsberg, J.S., Douketis, J.D., Holbrook, A.M. & Cheah, G. (2000) A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Archives of Internal Medicine, 160, 181-188.
11. Eikelboom, J.W., Anand, S.S., Malmberg, K., Weitz, J.I., Ginsberg, J.S. & Yusuf, S. (2000) Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet, 355, 1936-1942.
12. Ellison, J., Thomson, A.J., Conkie, J.A., McCall, F., Walker, D. & Greer, A. (2001) Thromboprophylaxis following caesarean section. A comparison of the antithrombotic properties of three low molecular weight heparins: dalteparin, enoxaparin and tinzaparin. Thrombosis and Haemostasis, 86, 1374-1378.
13. Eriksson, B.I., Soderberg, K., Widlund, L., Wandeli, B., Tengborn, L. & Risberg, B. (1995) A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thrombosis and Haemostasis, 73, 398-401.
14. Eriksson, B.I., Arfwidsson, A.C., Frison, L., Eriksson, U.G., Bylock, A., Kalebo, P., Fager, G. & Gustafsson, D. (2002) A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thrombosis and Haemostasis, 87, 231-237.
15. Fareed, J., Jeske, W., Hoppensteadt, D., Clarizio, R. & Walenga, J.M. (1996) Are the available low-molecular-weight heparin preparations the same? Seminars in Thrombosis and Hemostasis, 22, 77-91.
16. Fareed, J. Hoppensteadt, D., Jeske, W., Clarizio, R. & Walenga, J.M. (1998) Low molecular weight heparins: are they different? Canadian Journal of Cardiology, 14, 28e-34e.
17. Fragmin and Fast Revascularisation during Instability in Coronary Artery Disease Investigators (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease; FRISC II prospective randomised multicentre study. Lancet, 354, 708-715.
18. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group (1996) Low-molecular-weight heparin during instability in coronary artery disease. Lancet, 347, 561-568.
19. Freedman, K.B., Brookenthal, K.R., Fitzgerald, Jr. R.H., Williams, S. & Lonner, J.H. (2000) A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. Journal of Bone Joint Surgery of America, 82A, 929-938.
20. Geerts, W.H., Heit, J.A., Clagett, G.P., Pineo, G.F., Colwell, C.W., Anderson, Jr. F.A. & Wheeler, H.B. (2001) Prevention of venous thromboembolism, Chest, 119, 132s-175s.
21. Gori, A.M., Fedi, S., Pepe, G., Falciani, M., Rogolino, A., Prisco, D., Gensini, G.F. & Abbate, R. (2002) Tissue factor and tissue factor pathway inhibitor levels in unstable angina patients during short-term low-molecular-weight heparin administration. British Journal of Haematology, 117, 693-698.
22. Gould, M.K., Dembitzer, A.D., Sanders, G.D. & Gather, A.M. (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Annals of Internal Medicine, 130, 789-799.
23. Group, T.S. (1999) Thromoboprophylaxis in hip fracture surgery: a pilot study comparing danaparoid, enoxaparin and dalteparin. Haemostasis, 29, 310-317.
24. Gurfinkel, E.P., Manos, E.J., Mejail, R.I., Cerda, M.A., Duronto, E.A., Garcia, C.N., Daroca, A.M. & Mautner, B. (1995) Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology, 26, 313-318.
25. van der Heijden, J.F., Prins, M.H. & Büller, H.R. (2000) For the initial treatment of venous thromboembolism: are all low-molecular-weight heparin compounds the same? Thrombosis Research, 100, V121-V130.
26. Hirsh, J., Dalen, J.E., Anderson, D.R., Poller, L., Bussey, H., Ansell, J., Deykin, D. & Brandt, J.T. (1998) Oral Anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest Supplement, 114, 445s-469s.
27. Hodl, R., Huber, K., Kraxner, W., Nikfardjam, M., Schumacher, M., Fruhwald, F.M., Zorn, G., Wonisch, M. & Klein, W. (2002) Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. American Journal of Cardiology, 89, 589-592.
28. Hull, R., Raskob, G., Pineo, G., Rosenbloom, D., Evans, W., Mallory, T., Anquist, K., Smith, F., Hughes, G., Green, D., Elliott, C.G., Panju, A. & Brant, R. (1993) A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. New England Journal of Medicine, 329, 1370-1376.
29. Hyers, T.M., Agnelli, G., Hull, R.D., Morris, T.A., Samama, M., Tapson, V. & Weg, J.G. (2001) Antithrombotic therapy for venous thromboembolic disease. Chest, 119, 176s-193s.
30. Kaul, S. & Shah, P.K. (2000) Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin? Journal of the American College of Cardiology, 35, 1699-1712.
31. Klein, W., Buchwald, A., Hillis, S.E., Monrad, S., Sanz, G., Turpie, A.G., van der Meer, J., Olaisson, E., Undeland, S. & Ludwig, K. (1997) Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation, 96, 61-68.
32. Koch, A., Ziegler, S., Breitschwerdt, H. & Victor, N. (2001) Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thrombosis Research, 102, 295-309.
33. Krotenberg, R., Adler, U., Pomeranz, B., Miller, J.D. & Russell, M.W. (2001) Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. American Journal of Physical and Medical Rehabilitation, 80, 889-895.
34. Leizorovicz, A., Bara, L., Samama, M.M. & Haugh, M.C. (1993) Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis, 23, 89-98.
35. Lindahl, A.K., Abildgaard, U. & Staalesen, R. (1991) The anti-coagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thrombosis Research, 64, 155-168.
36. Lopez, L.M. (2001) Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism. Pharmacotherapy, 21, 56s-61s, 71s-72s.
37. McCart, G.M. & Kayser, S.R. (2002) Therapeutic equivalency of low-molecular-weight heparins. Annals of Pharmacotherapy, 36, 1042-1057.
38. Mismetti, P., Laporte-Simitsidis, S., Tardy, B., Cucherat, M., Buchmuller, A., Juillard-Delsart, D. & Decousus, H. (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thrombosis and Haemostasis, 81, 14-19.
39. Mismetti, P., Laporte, S., Darmon, J.Y., Buchmuller, A. & Decousus, H. (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. British Journal of Surgery, 88, 913-930.
40. Montalescot, G., Collet, J.P., Lison, L., Choussat, R., Ankri, A., Vicaut, E., Perlemuter, K., Philippe, F., Drobinski, G. & Thomas, D. (2000) Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. Journal of the American College of Cardiology, 16, 110-114.
41. Morris, T.A., Marsh, J.J., Konopka, R., Pedersen, C.A. & Chiles, P.G. (2000) Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thrombosis Research, 100, 185-194.
42. Oosta, G.M. Gardner, W.T., Beeler, D.L. & Rosenberg, R.D. (1981) Multiple functional domains of the heparin molecule. Proceedings of the National Academy of Sciences of the United States of America, 78, 829-833.
43. Palmer, A.J., Koppenhagen, K., Kirchhof, B., Weber, U. & Bergemann, R. (1997) Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis, 27, 75-84.
44. Planès, A., Samama, M.M., Lensing, A.W., Büller, H.R., Barre, J., Vochelle, N. & Beau, B. (1999) Prevention of deep vein thrombosis after hip replacement: comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thrombosis and Haemostasis, 81, 22-25.
45. Racine, E. (2001) Differentiation of the low-molecular-weight heparins. Pharmacotherapy, 21, 62S-70S; discussion 71S-72S.
46. Schumock, G.T., Nutescu, E.A., Walton, S.M., Arondekar, B.V. & Lewis, R.K. (2002) Survey of hospital policies regarding low-molecular-weight heparins. American Journal of Health System Pharmacology, 59, 534-538.
47. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators (1997) Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. Journal of the American College of Cardiology, 29, 1474-1482.
48. Verheugt, F.W. (1999) Hotline sessions at the 20th European Congress of Cardiology, European Heart Journal, 20, 7-10.
49. Weitz, J.I. (1997) Low-molecular-weight heparins. New England Journal of Medicine, 337, 688-698.
50. Welis, P.S., Rodger, M., Forgie, M., Anderson, D.M.K., Florack, P., Touchie, D., Morrow, B. & Dubey, N. (2001) A randomized trial comparing two low molecular weight heparins (LMWHs) for the outpatient treatment of DVT or PE. Thrombosis and Haemostasis, 86s, 968.
51. Westrich, G.H., Haas, S.B., Mosca, P. & Peterson, M. (2000) Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. British Journal of Bone Joint Surgery, 82, 795-800.